Evaluate Discovery
NEWSLETTER
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Featured Report: Obesity – The Next Questions
Before the incretin drug class proved its potential, the notion that obesity could be treated with a pill or injection was almost science fiction. Now, it’s very much fact and the big question is; how large could this market become?
Register to sign up for Evaluate's Discovery newsletter, including the latest thought leadership & news.
Looking for more? Scroll down for more of our latest content on the hottest topics in pharma.
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Have you downloaded your copy of the World Preview 2024 report?
Have you downloaded your copy of the World Preview 2024 report? It’s our annual dive into the latest forecasts for the pharma market and if you’ve not read it yet, you can find it here. Featuring expert analysts and tonnes of data, it’s a must-read for anyone who needs to understand the direction of the market, from key players to top pipeline projects.
E-BOOK
One Step Forward; Q2 Steps Back
In this eBook, we explore the ups and downs of what is clearly still a very bumpy recovery around M&A, IPOs and venture financing. As we head into the second half of the year, will we be able to take more steps forward?
INFOGRAPHIC
Quarterly Round Up: One Step Forward, Q2 Steps Back
2024 began on a hopeful note, yet as we moved into the second quarter, M&A activity slowed, and IPOs saw a significant downturn. View our latest Quarterly Round-Up infographic for a high-level view of these key trends.
E-BOOK
Billion Dollar Blueprint: The Journey to Blockbuster Status
Learn about the role that indications play, the typical timeline to reach blockbuster status, and the advantages of developing drugs internally versus outsourcing.
INFOGRAPHIC
Billion Dollar Blueprint: The Journey to Blockbuster Status
Get your copy of the Billion Dollar Blueprint infographic now to explore the essential data and insights behind the pharma industry’s powerhouses.
Blog
Meet the Team: Kelly Chamberlain
Catch up with Kelly to talk about her approach to leadership, background in neuroscience and what she has in common with small children
BLOG
In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar
Missed our webinar about AI in pharma forecasting? Fear not, we have a blog post with a few highlights for you. And the webinar featuring J+D Forecasting is available on-demand!
